STOCK TITAN

RPRX (NASDAQ: RPRX) insider files to sell 108,424 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

RPRX filed a notice of proposed insider sales of common stock under Rule 144. The filing covers up to 108,424 common shares to be sold through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $4,592,840.64 and 427,247,489 shares outstanding.

The seller reports acquiring 102,581 shares on 06/16/2020 from the issuer in a private transaction and 5,843 shares on 02/12/2020 as compensation through performance awards. The notice also lists multiple recent common stock sales over the past three months by TPC RP EPA1 LLC and TPC RP 2021 LLC, each generating six-figure gross proceeds.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the RPRX Form 144 filing disclose?

The Form 144 filing discloses a proposed sale of up to 108,424 shares of RPRX common stock. The shares have an aggregate market value of $4,592,840.64 and are planned to be sold through Goldman Sachs & Co. LLC on the NASD exchange around 02/02/2026.

How many RPRX shares are planned for sale and what is their value?

The filing covers a planned sale of 108,424 RPRX common shares. These shares have an aggregate market value of $4,592,840.64, based on the information provided, and are to be sold through Goldman Sachs & Co. LLC under Rule 144 on the NASD exchange.

When and how were the RPRX shares in the Form 144 acquired?

The seller acquired 102,581 RPRX common shares on 06/16/2020 from the issuer in a private transaction. An additional 5,843 shares were acquired on 02/12/2020 as compensation through performance awards, with payment described as compensation rather than cash.

How many RPRX shares are outstanding according to this filing?

According to the filing, 427,247,489 RPRX common shares are outstanding. This figure provides context for the relative size of the proposed 108,424-share sale disclosed under Rule 144 in relation to the total existing share count of the issuer.

What recent RPRX stock sales are reported for the past three months?

The filing lists multiple RPRX common stock sales over the past three months by TPC RP EPA1 LLC and TPC RP 2021 LLC. These transactions occurred on several dates in November 2025, December 2025, and January 2026, each generating substantial gross proceeds in the five- to seven-figure range.

Which broker and exchange are involved in the proposed RPRX share sale?

The proposed sale of 108,424 RPRX common shares is to be executed through Goldman Sachs & Co. LLC as broker. The filing specifies that the shares are expected to trade on the NASD exchange, with an approximate sale date of 02/02/2026.
Royalty Pharma Plc

NASDAQ:RPRX

RPRX Rankings

RPRX Latest News

RPRX Latest SEC Filings

RPRX Stock Data

18.84B
387.98M
8.74%
82.44%
3.85%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK